|
antibody |
11 |
|
influenza |
8 |
|
transmission |
7 |
|
antibodies |
6 |
|
coronavirus |
6 |
|
elisa |
6 |
|
immunogenicity |
6 |
|
vaccination |
6 |
|
china |
4 |
|
coronavirus disease 2019 |
4 |
|
covid‐19 |
4 |
|
cytokines |
4 |
|
epidemiology |
4 |
|
guangdong |
4 |
|
influenza virus |
4 |
|
intensive care unit |
4 |
|
sars-cov-2 |
4 |
|
sars‐cov‐2 |
4 |
|
serology |
4 |
|
seroprevalence |
4 |
|
avian influenza |
3 |
|
coronavirus disease 2019 (covid-19) |
3 |
|
immune response |
3 |
|
influenza vaccines |
3 |
|
neutralization assay |
3 |
|
next-generation sequencing |
3 |
|
nucleocapsid |
3 |
|
pandemic influenza a virus |
3 |
|
pregnancy |
3 |
|
zoonosis |
3 |
|
acute respiratory tract infection |
2 |
|
adjuvants |
2 |
|
airborne transmission |
2 |
|
animal model |
2 |
|
antibody responses |
2 |
|
antiviral |
2 |
|
antiviral resistance |
2 |
|
avian |
2 |
|
avian influenza virus |
2 |
|
cellular immunity |
2 |
|
children |
2 |
|
covid-19 |
2 |
|
egg-adaptation |
2 |
|
epidemic |
2 |
|
ferret |
2 |
|
ferret model |
2 |
|
ferrets |
2 |
|
h10n1 |
2 |
|
h1n1 |
2 |
|
h4n2 |
2 |
|
h7n9 |
2 |
|
hemagglutinin |
2 |
|
human adenovirus |
2 |
|
humoral immunity |
2 |
|
immune correlate |
2 |
|
immunity |
2 |
|
infection |
2 |
|
influenza a(h3n2) |
2 |
|
influenza b virus |
2 |
|
list of abbreviations. |
2 |
|
low pathogenic avian influenza |
2 |
|
modeling |
2 |
|
monocytes |
2 |
|
mouse |
2 |
|
mucosal immunity |
2 |
|
multibasic cleavage site |
2 |
|
nasal turbinate |
2 |
|
neuraminidase |
2 |
|
nonstructural protein 1 |
2 |
|
novel vaccine platforms |
2 |
|
older adults |
2 |
|
outbreak |
2 |
|
pandemic |
2 |
|
polymerase |
2 |
|
public health |
2 |
|
quail |
2 |
|
respiratory virus |
2 |
|
seroconversion |
2 |
|
severe acute hepatitis |
2 |
|
severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
2 |
|
single-cell transcriptomics |
2 |
|
southern china |
2 |
|
stalk |
2 |
|
susceptible-exposed-infectious-removed (seir) |
2 |
|
t cell |
2 |
|
tree shrew |
2 |
|
universal vaccine |
2 |
|
vaccine |
2 |
|
vaccine effectiveness |
2 |
|
vaccines |
2 |
|
western pacific |
2 |
|
wild bird |
2 |
|
asia and the pacific |
1 |
|
autoimmunity |
1 |
|
b cell |
1 |
|
biomarker |
1 |
|
california |
1 |
|
chemokines |
1 |
|
colonization |
1 |
|
control |
1 |
|
cytokine |
1 |
|
cytokine. |
1 |
|
dengue |
1 |
|
dengue virus |
1 |
|
dengue viruses |
1 |
|
discrete event simulation (des) |
1 |
|
disease burden |
1 |
|
disease severity |
1 |
|
duck |
1 |
|
endoplasmic reticulum |
1 |
|
evolution |
1 |
|
fusion glycoprotein |
1 |
|
gene sequence analysis |
1 |
|
h10n8 |
1 |
|
h5 |
1 |
|
hemagglutination inhibition |
1 |
|
hemagglutination inhibition antibody |
1 |
|
heterosubtypic |
1 |
|
host-pathogen interactions |
1 |
|
human |
1 |
|
human infection |
1 |
|
iceland |
1 |
|
immunology |
1 |
|
in vitro model |
1 |
|
infection control |
1 |
|
influenza a virus |
1 |
|
influenza infection attack rate |
1 |
|
influenza-like illness |
1 |
|
innate immune response |
1 |
|
innate immunology |
1 |
|
ion channels |
1 |
|
lgg |
1 |
|
live poultry market |
1 |
|
localisation |
1 |
|
lpai |
1 |
|
m protein |
1 |
|
membrane fusion |
1 |
|
monocyte |
1 |
|
natural influenza virus infection |
1 |
|
neuraminidase inhibition |
1 |
|
neuraminidase inhibition antibody |
1 |
|
neutralizing |
1 |
|
nosocomial infection |
1 |
|
nucleic acid detection |
1 |
|
oligomerisation |
1 |
|
phylodynamics |
1 |
|
phylogeny |
1 |
|
pneumococci |
1 |
|
prm |
1 |
|
probiotic |
1 |
|
process optimization |
1 |
|
reverse transcription polymerase chain reaction (rt-pcr) |
1 |
|
risk factors |
1 |
|
seroepidemiologic cohort |
1 |
|
subarctic |
1 |
|
universal influenza vaccine |
1 |
|
viral |
1 |
|
wild birds |
1 |
|
xenopus oocytes |
1 |
